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Abstract
Background: With the increasing number of non palpable breast carcinomas, the need of a good
and reliable localization method increases. Currently the wire guided localization (WGL) is the
st a n d a rd  o f  c a r e  i n  m o st  c o u n t ri e s .  R a d i o gu i d e d  occult lesion localization (ROLL) is a new
technique that may improve the oncological outcome, cost effectiveness, patient comfort and
cosmetic outcome. However, the studies published hitherto are of poor quality providing less than
convincing evidence to change the current standard of care.
The aim of this study is to compare the ROLL technique with the standard of care (WGL) regarding
the percentage of tumour free margins, cost effectiveness, patient comfort and cosmetic outcome.
Methods/design: The ROLL trial is a multi center randomized clinical trial. Over a period of 2–3
years 316 patients will be randomized between the ROLL and the WGL technique. With this
number, the expected 15% difference in tumour free margins can be detected with a power of 80%.
Other endpoints include cosmetic outcome, cost effectiveness, patient (dis)comfort, degree of
difficulty of the procedures and the success rate of the sentinel node procedure.
The rationale, study design and planned analyses are described.
Trial Registration: (http://www.clinicaltrials.gov, study protocol number NCT00539474)
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Background
The early detection of breast malignancies decreases the
mortality and morbidity of breast cancer patients. These
early-detected tumours are generally small and non-pal-
pable.
Wire Guided Localization (WGL), is currently the most
commonly used localization method for non-palpable
breast lesions. This technique uses a wire to localize the
lesion to be excised. The wire can be inserted under stere-
otactic or ultrasonographic guidance. WGL has several
known disadvantages: the radiologically guided wire
placement is technically difficult, particularly in dense
breast tissue (the wire can displace and reposition is often
restricted because of the hook fixed in the tissue). Surgical
excision of a lesion with clear histological margins follow-
ing wire localization is demanding as well. Finally,
patients experience the inserted wire as painful and
uncomfortable and there is a small risk of a pneumotho-
rax [1-3].
The Radio Occult Lesion Localization (ROLL) introduced
in 1998, is a new technique to localize the non-palpable
breast tumour[4]. The ROLL technique utilizes the intra-
tumourally injected radiofarmaceutical that is used for
lymphatic mapping and sentinel node biopsy (SNB). In
the same surgical procedure, this tracer can be used to
localize the primary tumour guided by the gamma probe.
Previous small non randomized trials, comparing WGL
and ROLL have found the ROLL technique to be simpler
and faster to perform, potentially resulting in fewer costs
associated with the use of ultrasound, operation rooms
and hospital stay [5].
Methods/Design
Design
A multicenter, prospective randomized clinical trial. Eligi-
ble patients will be randomized for either radio guided
occult lesion localization (ROLL) or wire guided localiza-
tion (WGL).
Subjects
Three hundred and sixteen patients will be recruited in 2
years in a University Medical Center and medium sized to
large hospitals in the Netherlands.
All patients will have confirmed occult breast cancer (core
needle biopsy proven) and need to be treated with a
lumpectomy and sentinel node biopsy. Written informed
consent will be obtained from all patients. This study has
been approved by the ethical board of the university med-
ical center Utrecht.
Patient selection
All patients will be selected based on the in- and exclu-
sion-criteria. The inclusion of patients will take place at
the outpatient clinic in the participating hospitals.
Patients will be informed about this trial by both written
and oral explanation. Given the number of regular treat-
ments of occult breast tumours in the collaborating hos-
pitals (250–300 patients per year), the aim to finish the
inclusion in 2 years is considered realistic.
Women ≥18 years with a non palpable breast carcinoma
(cT1) that need to be treated with breast conserving sur-
gery are asked to participate. Exclusion criteria are preg-
nancy, multifocal tumour growth, in situ ductal
carcinoma only, lobular in situ carcinoma only and
patients requiring breast amputation.
Randomization
Randomization is stratified for hospital. In each hospital,
randomization within strata is blocked with a fixed block
size. Randomization is performed by an independent trial
center. If a patient meets the inclusion criteria and has
provided informed consent, the physician contacts the
trial center by phone. The trial center will perform the ran-
domization of the patients.
Time schedule
Patient recruitment will take place between 2008 and
2010.
ROLL procedure
Patients in the ROLL group will undergo intratumoural
injection of the radiofarmaceutical under stereotactic or
ultrasound guidance. After scintigraphic imaging, 1, 2 or
if necessary 3 hours post injection, the excision of the pri-
mary tumour and the sentinel node procedure are both
guided by a gamma probe. At the site of maximum counts
with the gamma probe (Europrobe, Strassbourg, France)
patent blue (Bleu patenté V 'Guerbet')is injected intratu-
mourally (see Figure 1).
As with all localization techniques, care is required in the
initial placement of the lesion marker. A few studies have
described failures in placement of the radioactive marker.
However, the tracer was positioned correctly in 95–99%
of patients[6,7]. After localization, the surgical excision is
guided by the probe at its lowest sensitivity setting. The
exact site of the lesion can be checked constantly during
the procedure by using the probe. In this way centering of
the lesion within the specimen can be achieved, poten-
tially resulting in a smaller quantity of removed tissue and
a higher chance of achieving tumour free margins.BMC Surgery 2008, 8:9 http://www.biomedcentral.com/1471-2482/8/9
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Flowchart Figure 1
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WGL procedure
Patients in the WGL group will receive a guide wire, posi-
tioned intratumourally under ultrasonigraphic or stereo-
tactic guidance after  the scintigrafic imaging 1, 2 or 3
hours post injection. The excision of the tumour is guided
by the inserted wire and the sentinel node procedure is
performed using per operatively injected patent blue and
a gamma probe. This is the current golden standard.
Outcome parameters
The outcome parameters are tumour free margins (and
number of re-excisions), resection specimen volume, cos-
metic outcome, quality of life, cost effectiveness also par-
ticipating physicians will score the difficulty of the
procedures. Patients will be asked to fill in questionnaires
on pain during the procedure, quality of life and the cos-
metic outcome. A specific burden questionnaire, aimed at
evaluating the burden of the cosmetic result, is developed.
Such an instrument is currently not available. To further
assess the net impact in terms of Health Related Quality of
Life (HRQoL) also the EQ5D and the EQVAS will be
obtained at T = 0, 6, 12 and 26 weeks after the initial diag-
nostic work-up.
The outcome of the study can be divided in 3 groups of
outcome; negative outcomes, outcomes open to discus-
sion and positive outcomes.
Less tumour free margins in the ROLL group are consid-
ered negative outcomes, also more tumour free margins in
combination with a larger resection volume is a negative
outcome and equal tumour free resection margins com-
bined with larger resection specimens are considered neg-
ative. Secondly outcomes open to discussion are more
tumour free margins in combination with an equal resec-
tion volume and equal resection margins in combination
with smaller resection specimens in the ROLL group.
Finally positive outcomes are more tumour free resection
margins in combination with smaller resection specimens
and equal tumour free margins in combination with
smaller resection specimens. These data will be based on
pathology reports. All surgical specimens will be analysed
by one dedicated reference pathologist (PvD).
The overall outcome will be cost-effectiveness in terms of
incremental costs per quality adjusted life years gained
with a 6 month time horizon. We hypothesize that the
short-term burden will result in an overall superior result
after ROLL.
When indeed our expectations are evidenced, than a situ-
ation of dominance may occur, i.e., costs may be saved
while at the same time clinical effects are optimal after
ROLL.
Should the results indicate that overall the WGL proce-
dure leads to better clinical outcome a cost-effectiveness
analysis is foreseen using bootstrapping to assess the
uncertainty with regard to the balance between costs and
effects. All analyses will be limited to a half year time hori-
zon. Accordingly, discounting of costs or effects is not
applicable.
Sample size
Sample size is calculated based on the primary endpoint:
tumour free margins. Based on currently available litera-
ture we assume a difference in tumour free margins of
15% in favor of the ROLL procedure [8-14]. With a statis-
tical power of 80% to detect this 15% improvement as sig-
nificant (p < 0.05), we will require 158 patients in the
control (WGL) group and 158 in the ROLL group.
Assuming a weight of 50 gr in the WGL group and a differ-
ence of 10 gr in the ROLL group [15] and a standard devi-
ation of 3 gr, α = 0.05 and β = 0.80, the groups are
sufficient to show a significant reduction in weight.
Economic evaluation
The goal of the economic evaluation is to assess the bal-
ance between costs and effects of ROLL versus WGL. The
principal underlying assumption is that once tumour free
margins are obtained the prognosis will be similar.
Therefore, long term analyses will not be necessary. In fact
ignoring the possible difference in burden associated with
WGL as compared to ROLL a cost-minimization would
suffice. This is the initial approach, i.e., comparing actual
costs incurred with both strategies up until 6 months after
the first operation. Costs estimates will be based on the
actual costs of both procedures. This includes the costs of
operation rooms, hospital stay, ultrasound/stereotactic
imaging, wire placement, gamma probe use and if neces-
sary, costs associated with complications and re-opera-
tions.
To assess the impact of the psychological burden of pro-
longed uncertainty regarding curative excision and the
psychological burden associated with re-operation, dedi-
cated questionnaires are developed.
Finally, there is a possibility that after ROLL, on average, a
larger part of the breast is excised leading to less satisfac-
tory cosmetic results. This is evaluated by interviewing the
patients on their appreciation of the shape and appear-
ance of their breast.
Statistical analysis
The difference in radicality of the resected specimen in
both groups will be calculated in a confidence interval
(CI) of 95%.BMC Surgery 2008, 8:9 http://www.biomedcentral.com/1471-2482/8/9
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The volume of the specimens is presented in mm3 and the
maximum diameter in mm. The approach for the cost-
analysis is comparing actual costs incurred with both
strategies up until 6 months after the first operation. Costs
estimates will be based on the actual costs of both proce-
dures. This includes the costs of operation rooms, hospital
stay, ultrasound/stereotactic imaging, wire placement,
gamma probe use and if necessary, costs associated with
complications and re-operations.
The degree of difficulty of radiological and surgical proce-
dure will be expressed on a 1–10 scale (1 being extremely
easy and 10 extremely difficult). The average score for
both procedures will be calculated. Patient discomfort of
the radiological procedure is expressed on 1–10 scale to (1
being not painful and 10 being very painful).
The success rate of the sentinel node procedure is pre-
sented in a percentage of successfully detected and found
sentinel nodes.
The weight and size of the surgical specimens as well as
the degree of difficulty of the surgical and radiological
procedures and patients discomfort in both groups will be
analyzed using the students T test.
The cost-effectiveness analysis will be done using the mul-
tivariate analysis. If the baseline characteristics differ after
randomization, i.e. there is a lack of balance in the con-
founding factors, this will be corrected using the multivar-
iate analysis.
Discussion
The purpose of the ROLL trial is to compare the standard
of care (WGL) with the ROLL procedure on oncological
outcome, cost effectiveness, cosmetic outcome, patient
comfort and learning curve for the participating physi-
cians.
As published previously by our group, the published stud-
ies so far indicate a benefit of the ROLL procedure, but are
not conclusive [5]. So far only 1 randomized clinical trial
is available, but this trial lacks essential information on
tumour free margins and tumour size [16].
A large trial on ROLL published recently including 368
patients showed tumour free margins in 89% of the cases
and a 97% identification rate of the sentinel node [17].
These figures are encouraging, but the patients in this
study were not randomized, and a hook wire was always
inserted at the primary tumour site. In our opinion this
will not improve patient comfort and the technique is not
easier to perform.
In some studies, patients with non palpable invasive car-
cinoma, carcinoma in situ and benign lesions were
included [18,19]. However, patients with an invasive car-
cinoma are likely to benefit the most from the ROLL tech-
nique. As these patients have to undergo a SNB, they will
have to undergo one procedure less, i.e. the placement of
a wire.
To the best of our knowledge none of the studies pub-
lished have evaluated cost-effectiveness. In order to imple-
ment the new procedure nationwide, besides oncological
outcome the cost-effectiveness should be balanced to
make this the new standard of care. Approximately 4.000
out of 13.000 women diagnosed with breast cancer need
wire guided localization and a sentinel node procedure.
Our hypothesis, based on the current literature, is that
15% (600 patients) less re-operations are necessary after
treatment with the ROLL technique. A re-operation costs
about € 7000, so eventually € 4.200.000 a year might be
saved by this method. Furthermore, abandoning the radi-
ological wire insertion procedure and the shorter surgical
operating times could provide an additional cost reduc-
tion.
In conclusion, the ROLL trial aims to prove oncological,
patient satisfaction and cost effective superiority of the
ROLL technique versus the WGL technique in the treat-
ment of patients with a non palpable breast carcinoma.
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